According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Randomized controlled trial with pharmacokinetic sampling
To test if oral 5 kDa hyaluronic acid distributes systemically, adult female C57BL/6J mice would be randomly assigned to receive either 5 kDa hyaluronic acid orally or a placebo, with blood and tissue samples (eyes, bladder, vagina, rectum) collected at multiple time points over 7 days and analyzed via mass spectrometry for hyaluronic acid concentration. Tissue-specific biodistribution study with fluorescent labeling
To visualize and confirm systemic distribution, 5 kDa hyaluronic acid would be labeled with a non-toxic fluorescent tag and administered orally to adult female C57BL/6J mice; tissues (eyes, bladder, vagina, rectum) would be excised at 24, 48, 72, 96, 120, 144, 168 hours and imaged using confocal microscopy to detect fluorescence above background. Controlled cross-over pharmacokinetic study with tissue extraction
To confirm systemic absorption, each mouse would receive both oral 5 kDa hyaluronic acid and oral saline in randomized order with a washout period; tissues would be harvested and analyzed for hyaluronic acid content using ELISA or HPLC to compare concentrations between treatment and control conditions. Dose-response study with multiple molecular weight controls
To determine if the 5 kDa size is critical for systemic distribution, mice would receive oral doses of 5 kDa, 50 kDa, and 500 kDa hyaluronic acid; tissue levels in eyes, bladder, vagina, and rectum would be compared to assess molecular weight dependence. Gut permeability and barrier integrity correlation study
To explore whether systemic detection is due to gut leakage, mice would be treated with oral 5 kDa hyaluronic acid while simultaneously measuring intestinal permeability (e.g., FITC-dextran assay) and gut histology to correlate tissue levels with barrier disruption.